Zoetis (ZTS) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.56 per share a year ago.
Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares surging abou
There are many reasons to invest in dividend stocks. Companies that offer regular payouts tend to have strong underlying operations and generate consistent revenue and profits, making them excellent c
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2025 and raised its full year 2025 guidance. The company
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart
In the latest trading session, Zoetis (ZTS) closed at $148.81, marking a -1.46% move from the previous day.
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The flow of information is constant and sometimes overwhelming on Wall Street. Trying to interpret an onslaught of earnings reports and monthly economic data releases each quarter can easily allow som
Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value

Zoetis (ZTS) Laps the Stock Market: Here's Why

07:15pm, Tuesday, 22'nd Jul 2025
In the most recent trading session, Zoetis (ZTS) closed at $151.19, indicating a +2.59% shift from the previous trading day.
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis Inc. is the dominant animal health company, growing market share, revenue, and margins, now trading at a multi-year low valuation. Fundamentals remain strong: rising EPS, aggressive buybacks, a

Here's Why Zoetis (ZTS) is a Strong Growth Stock

10:46am, Thursday, 17'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
JPMorgan upgraded Phibro Animal Health Corporation PAHC, citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfolio.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE